Survodutide
Survodutide (BI 456906) is a synthetic glucagon-derived peptide acting as a dual GLP-1 and glucagon receptor agonist, studied for weight management and MASH/liver disease; research protocols use once-weekly subcutaneous dosing that starts low (around 0.6 mg) and titrates gradually toward a 3.6 mg or 6.0 mg weekly maintenance target.
Survodutide has been studied primarily for chronic weight management in adults with overweight or obesity, and for metabolic dysfunction-associated steatohepatitis (MASH/NASH) with liver fibrosis; it has also been evaluated in type 2 diabetes contexts. Research use only — not an FDA-approved product.
Survodutide (research designation BI 456906) is a 29-amino-acid synthetic peptide derived from the glucagon backbone and engineered to co-activate two receptors: the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Structurally it carries a non-coded Ac4c residue at position 2 and a C18 fatty-diacid conjugation that binds circulating albumin, extending the half-life enough to support once-weekly subcutaneous dosing. Mechanistically, GLP-1R activation enhances glucose-dependent insulin secretion, suppresses glucagon-driven glucose output, slows gastric emptying, and reduces appetite via central pathways; GCGR activation is studied for increasing energy expenditure and influencing hepatic lipid metabolism, which is the rationale for its investigation in fatty liver disease (MASH).
This dual GCGR/GLP-1R pharmacology places it in the same broad class as mazdutide (oxyntomodulin analog) but distinct from GLP-1-only agents (semaglutide) and GLP-1/GIP agents (tirzepatide). Developed by Boehringer Ingelheim and Zealand Pharma, survodutide is not FDA-approved and remains an investigational research compound; a research-use vial is not a branded pharmaceutical product and may vary in identity, purity, and content.
Published trials (Phase 2 and the Phase 3 SYNCHRONIZE program) use a once-weekly subcutaneous injection with slow, stepwise dose escalation over several weeks — beginning at a low starting dose and titrating toward a weekly maintenance dose of 3.6 mg or 6.0 mg. Conservative research framing: start at the lowest step (~0.6 mg/week), hold each step for roughly 2-4 weeks, and only advance if well tolerated. The slow ramp exists specifically to let the gut adapt and reduce nausea; do not skip steps. Confirm any plan with a qualified physician.
Research reports gradual effects: appetite changes are typically observed within the first weeks, with progressive body-weight reduction accumulating over many months across the multi-week titration; Phase 2 data reported roughly 12-15% mean weight loss over about 46 weeks at higher doses, and some trials had not reached a weight plateau by study end.
In research and trial contexts survodutide is generally used on its own as a foundational agent rather than stacked, studied alongside lifestyle and dietary interventions rather than combined with other incretin peptides. Stacking multiple GLP-class agonists is not supported by the research and compounds their GI and heart-rate effects.
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.